חזרה לתוצאות החיפוש

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

ישראלמגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Ovarian Cancer Recurrent

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Rambam Health Care Campus ( Site 0202), Haifa, Israel

    Study coordinator · 972-4-7776234

  • Shaare Zedek Medical Center ( Site 0201), Jerusalem, Israel

    Study coordinator · +972-(0)2-6555424

  • Rabin Medical Center ( Site 0203), Petah Tikva, Israel

    Study coordinator · +97239378076

  • Sheba Medical Center ( Site 0200), Ramat Gan, Israel

    Study coordinator · 972-3-5304498

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019), New Haven, Connecticut, United States

    Study coordinator · 203-785-2404

  • The University of Louisville, James Graham Brown Cancer Center ( Site 0009), Louisville, Kentucky, United States

    Study coordinator · 502-562-3429

  • Dana-Farber Cancer Institute ( Site 0015), Boston, Massachusetts, United States

    Study coordinator · 877-338-7425

  • Memorial Sloan Kettering Cancer Center ( Site 0003), New York, New York, United States

    Study coordinator · 212-639-2000

  • OU Health University of Oklahoma Medical Center ( Site 7000), Oklahoma City, Oklahoma, United States

    Study coordinator · 405-271-1112

  • Texas Oncology - DFW ( Site 8000), Fort Worth, Texas, United States

    Study coordinator · 615-329-7430

  • Houston Methodist Hospital ( Site 0010), Houston, Texas, United States

  • START Mountain Region ( Site 0008), West Valley City, Utah, United States

    Study coordinator · 801-907-4750

  • University of Virginia Health System ( Site 0011), Charlottesville, Virginia, United States

    Study coordinator · 434-924-9333

  • McGill University Health Centre ( Site 0100), Montreal, Quebec, Canada

    Study coordinator · 514-934-1934x31975

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0302), L'Hospitalet de Llobregat, Barcelona, Spain

    Study coordinator · +34932607744

  • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307), Majadhonda, Madrid, Spain

    Study coordinator · +34 911917358

  • Clinica Universidad de Navarra ( Site 0301), Madrid, Madrid, Comunidad de, Spain

    Study coordinator · +349135319207513

  • Hospital General Universitario de Valencia ( Site 0305), Valencia, Valenciana, Comunitat, Spain

    Study coordinator · +34 963187527

  • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300), Barcelona, Spain

    Study coordinator · +349325434528607

  • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303), Madrid, Spain

    Study coordinator · 34915504800 x2805

  • Hospital Universitario 12 de Octubre ( Site 0304), Madrid, Spain

    Study coordinator · +34913908626

  • Hospital Universitario Virgen de la Victoria ( Site 0306), Málaga, Spain

    Study coordinator · +34951032508

  • University Hospitals Sussex NHS Foundation Trust ( Site 0404), Brighton, East Sussex, United Kingdom

    Study coordinator · +44 01273 696 955

  • Royal Marsden Hospital ( Site 0402), Fulham, England, United Kingdom

    Study coordinator · +442078118084

  • The Royal Marsden NHS Foundation Trust. ( Site 0403), Sutton, England, United Kingdom

    Study coordinator · +442078118084

  • Barts Health NHS Trust ( Site 0401), London, London, City of, United Kingdom

    Study coordinator · 020 7377 7000

  • Guy s & St Thomas NHS Foundation Trust ( Site 0400), London, London, City of, United Kingdom

    Study coordinator · +44 020 7188 7188

  • The Christie NHS Foundation Trust ( Site 0405), Manchester, United Kingdom

    Study coordinator · +441619187689
מובילי המחקר

  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)